TPCW
NVO

TD Private Client Wealth’s Novo Nordisk NVO Stock Holding History

TD Private Client Wealth’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$401K Buy
8,359
+2,693
+48% +$116K 0.01% 554
2026
Q1 		$208K Sell
5,666
-7,397
-57% -$350K ﹤0.01% 639
2025
Q4 		$665K Buy
13,063
+6,343
+94% +$324K 0.01% 420
2025
Q3 		$373K Buy
6,720
+4,140
+160% +$242K 0.01% 536
2025
Q2 		$178K Sell
2,580
-331
-11% -$22.5K ﹤0.01% 661
2025
Q1 		$202K Sell
2,911
-103
-3% -$8.51K 0.01% 593
2024
Q4 		$259K Sell
3,014
-1,544
-34% -$167K 0.01% 550
2024
Q3 		$543K Sell
4,558
-358
-7% -$47.7K 0.02% 444
2024
Q2 		$702K Sell
4,916
-2,240
-31% -$297K 0.02% 396
2024
Q1 		$919K Sell
7,156
-6,115
-46% -$728K 0.03% 360
2023
Q4 		$1.37M Sell
13,271
-3,032
-19% -$300K 0.05% 286
2023
Q3 		$1.48M Buy
16,303
+1,781
+12% +$157K 0.06% 257
2023
Q2 		$1.18M Buy
14,522
+6,622
+84% +$541K 0.05% 304
2023
Q1 		$629K Sell
7,900
-1,934
-20% -$137K 0.03% 399
2022
Q4 		$665K Sell
9,834
-286
-3% -$16.8K 0.03% 382
2022
Q3 		$504K Sell
10,120
-120
-1% -$6.43K 0.03% 402
2022
Q2 		$571K Buy
10,240
+4,846
+90% +$269K 0.03% 394
2022
Q1 		$300K Sell
5,394
-924
-15% -$47.4K 0.01% 495
2021
Q4 		$354K Buy
6,318
+234
+4% +$12.7K 0.01% 470
2021
Q3 		$292K Buy
6,084
+2,078
+52% +$100K 0.01% 477
2021
Q2 		$168K Sell
4,006
-382
-9% -$14.8K 0.01% 545
2021
Q1 		$148K Sell
4,388
-700
-14% -$24.9K 0.01% 545
2020
Q4 		$178K Sell
5,088
-3,782
-43% -$131K 0.01% 495
2020
Q3 		$308K Sell
8,870
-1,502
-14% -$50.1K 0.02% 411
2020
Q2 		$340K Sell
10,372
-6,230
-38% -$199K 0.02% 393
2020
Q1 		$500K Buy
16,602
+3,892
+31% +$116K 0.04% 321
2019
Q4 		$368K Buy
+12,710
New +$352K 0.02% 388

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

TD Private Client Wealth's NVO Position: Q2 2026 in Review

TD Private Client Wealth increased its Novo Nordisk (NVO) stake by 48% in Q2 2026, buying an estimated $116K and bringing the position to 8,359 shares worth $401K. The position accounts for 0.01% of the portfolio, ranked #554.

TD Private Client Wealth first reported a position in NVO in Q4 2019 and has held it in 27 quarters since. The position peaked at $1.48M in Q3 2023. 1,353 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • TD Private Client Wealth held 8,359 shares of Novo Nordisk worth $401K as of Q2 2026.
  • TD Private Client Wealth bought 2,693 Novo Nordisk shares in Q2 2026, an estimated $116K.
  • Novo Nordisk made up 0.01% of TD Private Client Wealth's portfolio in Q2 2026, its #554 holding.
  • TD Private Client Wealth first reported a position in Novo Nordisk in Q4 2019 and has held it in 27 quarters since.
  • TD Private Client Wealth's Novo Nordisk position peaked at $1.48M in Q3 2023.
  • 1,353 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on TD Private Client Wealth's 13F filing for Q2 2026, filed 4 Aug 2026.